XIMINO Drug Patent Profile

When do Ximino patents expire, and what generic alternatives are available?

Ximino is a drug marketed by Journey and is included in one NDA. There are six patents protecting this drug.

This drug has twelve patent family members in nine countries.

The generic ingredient in XIMINO is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ximino

A generic version of XIMINO was approved as minocycline hydrochloride by WATSON LABS on December 30^th, 1991.

Summary for XIMINO

International Patents:	12
US Patents:	6
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	95
Patent Applications:	2,826
Drug Prices:	Drug price information for XIMINO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XIMINO
What excipients (inactive ingredients) are in XIMINO?	XIMINO excipients list
DailyMed Link:	XIMINO at DailyMed

See drug prices for XIMINO

US Patents and Regulatory Information for XIMINO

XIMINO is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		DISCN	No	No
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012		DISCN	No	No
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-002	Jul 11, 2012		DISCN	No	No
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		DISCN	No	No
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012		DISCN	No	No
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012		DISCN	No	No			Y

Expired US Patents for XIMINO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012
Journey	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012

International Patents for XIMINO

See the table below for patents covering XIMINO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010017310
World Intellectual Property Organization (WIPO)	2007001961
China	101208097	Method for the treatment of acne
Australia	2006262428	Method for the treatment of acne
Japan	2013213047	METHOD FOR TREATMENT OF ACNE
New Zealand	564093	Method for the treatment of acne using an oral minocycline antibiotic

XIMINO Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for XIMINO

Introduction

XIMINO, a brand name for minocycline hydrochloride extended-release capsules, is a key product in Journey Medical Corporation's dermatology portfolio. Here, we will delve into the market dynamics and financial trajectory of XIMINO, highlighting its performance, challenges, and future outlook.

Product Overview

XIMINO is an extended-release formulation of minocycline, approved by the FDA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It is notable for being the first and only extended-release minocycline capsule on the market, offering a safety profile similar to placebo due to its Capsular Minotab Technology[3].

Market Position

XIMINO has held a significant market position since its launch. As of 2022, it was the #1 prescribed branded minocycline in dermatology, with a 52% branded market share. The oral minocycline market, where XIMINO operates, had over 3 million prescriptions in 2021, indicating a substantial market size[3].

Financial Performance

Historical Revenue

XIMINO has been a revenue generator for Journey Medical Corporation since its acquisition and launch in September 2019. For the year ending December 31, 2020, XIMINO contributed $9.5 million to the company's revenue. In 2021, this figure slightly decreased to $8.2 million[3].

Quarterly Performance

In the first quarter of 2023, XIMINO's net product revenue was $0.6 million, down from $1.0 million in the first quarter of 2022. This decline is part of a broader trend where XIMINO's sales have been decreasing due to various market and competitive factors[5].

Recent Developments

As of the third quarter of 2023, Journey Medical Corporation discontinued the sale of XIMINO. This decision was likely influenced by declining sales and increasing competition from generic alternatives. The discontinuation of XIMINO has impacted the company's overall revenue, with net product revenues for XIMINO showing a significant decline in recent periods[2].

Competitive Landscape

Generic Competition

XIMINO faces significant competition from generic minocycline products. Although all formulations of XIMINO have been discontinued, the threat of generic competition remains. Generic versions of minocycline can erode the market share of branded products like XIMINO, leading to reduced sales and revenue[4].

Market Erosion

The discontinuation of XIMINO's various formulations (45mg, 67.5mg, 90mg, 112.5mg, and 135mg) has left the product vulnerable to generic competition. This erosion is evident in the declining sales figures and the company's decision to discontinue its sale[4].

Financial Impact

Revenue Decline

The decline in XIMINO sales has contributed to a decrease in Journey Medical Corporation's overall revenue from this product line. For instance, in the first quarter of 2024, the company reported a decrease in net product revenues for XIMINO, among other products, which was partially offset by growth in sales of Qbrexza and Accutane[2].

Operating Expenses

While the discontinuation of XIMINO has reduced some operational costs, the overall financial impact includes a decrease in revenue without a corresponding reduction in all expenses. This has affected the company's net loss, which remained significant in the first quarter of 2024[2].

Future Outlook

Strategic Focus

Journey Medical Corporation is shifting its focus towards other core products like Qbrexza and Accutane, which have shown growth potential. The company is also investing in new product development and acquisitions, such as the DFD-29 program for the treatment of rosacea, to diversify its revenue streams[2].

Market Adaptation

The discontinuation of XIMINO highlights the need for pharmaceutical companies to adapt quickly to changing market dynamics. Journey Medical Corporation's strategy to focus on products with stronger market positions and to develop new treatments will be crucial in maintaining and growing its revenue.

Key Takeaways

• Market Position: XIMINO was once the #1 prescribed branded minocycline in dermatology but has faced significant decline due to generic competition.
• Financial Performance: Revenue from XIMINO has decreased, contributing to the company's overall revenue decline from this product line.
• Competitive Landscape: Generic competition has eroded XIMINO's market share, leading to its discontinuation.
• Future Outlook: Journey Medical Corporation is focusing on other core products and new developments to maintain and grow its revenue.

FAQs

What is XIMINO used for?

XIMINO is used for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older[3].

Why was XIMINO discontinued?

XIMINO was discontinued due to declining sales and increasing competition from generic minocycline products[2][4].

How has the discontinuation of XIMINO affected Journey Medical Corporation's revenue?

The discontinuation of XIMINO has contributed to a decrease in Journey Medical Corporation's overall revenue from this product line, although this has been partially offset by growth in other products like Qbrexza and Accutane[2].

What is Journey Medical Corporation focusing on after the discontinuation of XIMINO?

The company is focusing on other core products like Qbrexza and Accutane and investing in new product development and acquisitions, such as the DFD-29 program for the treatment of rosacea[2].

What are the key challenges faced by XIMINO in the market?

XIMINO faced significant challenges from generic competition, which eroded its market share and led to its discontinuation[4].

Sources

1. Journey Medical Corporation SEC Filing: "Form 10-K" - Journey Medical Corporation, November 8, 2021.
2. Stock Titan: "Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights" - Stock Titan, May 13, 2024.
3. Journey Medical Corporation Company Overview: "JMC Company Overview" - Journey Medical Corporation, March 14, 2022.
4. Drugs.com: "Generic Ximino Availability" - Drugs.com, November 6, 2024.
5. Journey Medical Corporation Q1 2023 Investor Presentation: "Q1 2023 Investor Presentation" - Journey Medical Corporation, May 8, 2023.